INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) to hold its Annual General Meeting of Shareholders on May 25, 2010, in Marseilles, France

Transparency directive : regulatory news

21/04/2010 17:45

PRESS RELEASE

     INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON
                    MAY 25, 2010, IN MARSEILLES, FRANCE

Marseilles, France, April 21, 2010

Innate Pharma (Euronext Paris: FR0010331421 - IPH) will hold its Annual General
Meeting of Shareholders ("AGM") on May 25, 2010, at 10 am in its headquarters,
117 avenue de Luminy, F-13009 Marseille.

The Notice of Meeting of this Shareholders' Meeting was published on April
19, 2010, in the French official legal bulletin ("BALO").

Precision regarding the AGM:

Only shareholders having registered their shares at least three business days
prior to the date of the AGM, by midnight Paris time, will be able to attend.

Shareholders holding "au porteur" (bearer) shares will need to obtain an
"attestation de participation" (certificate of shareholding) from their brokers.
This "attestation de participation" must be attached to the proxy form or to the
appropriate voting form if shareholders wish to designate a proxy or vote by
mail. The "attestation de participation" may replace the admission card for
shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received from the day of the
publication of the official convocation to the AGM up until four business days
prior to the AGM (by registered letter, addressed to the registered office, or
by e-mail to investors@innate-pharma.com).

Shareholders may obtain the legal documentation in preparation of the AGM (as
described in article R. 225-83 of the French "Code de Commerce") by sending a
request:

* by regular mail to Innate Pharma, Shareholders Services, 117 avenue de Luminy,
  BP 30191, F-13009 Marseilles, France or

* by e-mail to investors@innate-pharma.com.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at
December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code                  FR0010331421
Ticker code                IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                 Alize Public Relations
Laure-Hélène Mercier          Caroline Carmagnol
Director, Investor Relations  Phone:  +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87   Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com   caroline@alizerp.com

IPH_AGM 2010

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) to hold its Annual General Meeting of Shareholders on May 25, 2010, in Marseilles, France

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories